Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

Abstract

Summary. -To design a vaccine that simultaneously prevents both rotavirus (RV) and poliovirus (PV), a PV type 1 (PV1) chimeric protein using RV VP6 as a vector (VP6F) was constructed, expressed in Escherichia coli expression system and characterized by SDS-PAGE, Western blot, immunofluorescence assay and neutralization test. The results showed that the chimeric protein reacted with anti-VP6F and anti-PV1 antibodies and elicited production of serum antibodies against the chimeric protein in guinea pigs. Antibodies against the chimeric protein neutralized RV Wa and PV1 infection in vitro. The results provided a relevant possibility of developing novel approaches in the rational design of vaccines effective against both RV and PV.Keywords: chimeric protein; neutralizing activity; rotavirus; poliovirus epitope * Corresponding author. E-mail: chenyd@imbcams.com.cn; phone: +86-871-68335402. Abbreviations: CPE = cytopathic effect; PV = poliovirus; RV = rotavirus; TCID 50 = 50% tissue culture infectivity doses

Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials

“…( A ) Different expression systems from prokaryotic E. coli [ 2 , 72 , 126 ] to eukaryotic systems such as yeast [ 17 ], insect cell/baculovirus systems (IC-BV) [ 38 , 67 ], mammalian cells [ 38 ], HSV-1 [ 90 ], and plant cells [ 37 , 89 , 127 ] have been used successfully to produce assembled structures of VP6 tubes/VLPs. ( B ) Applications of VP6 tubes/VLPs, as vaccines (immunogenicity and protection) [ 15 , 44 , 54 , 55 , 64 – 66 , 70 , 95 , 108 ], adjuvants [ 15 , 16 , 55 , 76 – 78 , 108 – 110 ], immunological carriers [ 49 , 53 , 92 , 96 , 102 , 111 ], drug delivery tools [ 5 , 91 , 122 , 126 ], and nano-biomaterials [ 5 , 23 , 24 , 41 , 42 , 50 , 91 , 122 , 126 ] …”

“…1 B) [ 49 , 102 ]. Since then, there have been many reports on the successful application of RV VP6 structured protein assemblies for chimeric Ag delivery, including insertion of (i) a 14-amino-acid peptide derived from the simian paramyxovirus 5 (V5 epitope) by genetic fusion [ 96 ], (ii) three epitopes of poliovirus type 1 (PV1) [ 92 ], (iii) three epitopes derived from the VP4 of RV [ 114 ], (iv) two peptides (23 and 140 amino acids) derived from the M2 and hemagglutinin (HA) genes of influenza A virus [ 53 ], and, more recently, (v) insertion of the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) to the surface loops or the N-terminus of VP6 without affecting protein conformation and immunogenicity [ 111 ]. The results of the immunization studies using these VP6-based chimeric Ag delivery systems in animal models have demonstrated the potency of VP6-based structured protein assemblies (VP6 tubes/VLPs) for induction of high titers of Abs and strong T-cell immune responses against both VP6 and the inserted Ag, suggesting the conformational conservation of both Ags in the chimera.…”

Rotavirus VP6 as a potential vaccine candidate

“…Assembled VP6 has also been used as an immunological carrier, which first documented as heterologous peptides coupled to VP6 VLPs elicited excellent humoral responses . Several studies further support that homologous and heterologous epitopes genetically fused to VP6‐based platform could improve immune response to foreign epitopes . Among different VP6 preparations, assembled VP6s appear to be considered as a potential RV vaccine platform due to the ability to present conserved epitopes.…”

“…90,91 Several studies further support that homologous and heterologous epitopes genetically fused to VP6-based platform could improve immune response to foreign epitopes. [92][93][94] Among different VP6 preparations, assembled VP6s appear to be considered as a potential RV vaccine platform due to the ability to present conserved epitopes.…”